Conceptio › Archive › Europe PMC
Europe PMCopen access

Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer

Liu M et al.
Europe PMC · Papers · License: Open Access
Open Source ↗Direct PDF ↓
chinacost
China, NSCLC, Cost-effectiveness, Capmatinib, Tepotinib
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗
Record · ID 4488
Conceptio Open Knowledge Archive — every document is proof-bundled with source, license, and retrieval metadata.